
2025-03-09
Ukuhanjiswa kweziyobisi ekujoliswe kuzo kumhlaza igxile ekuhambiseni ii-arhente zonyango ngokukodwa kwiiseli zomhlaza, ukunciphisa ingozi kwizihlunu eziphilileyo. Le ndlela isebenzisa iindlela ezahlukeneyo zobuchule, kubandakanya i-nanoparticles, i-antibodies, kunye ne-peptides engena kwiseli, ukunyusa ukusebenza kwechiza kunye nokunciphisa iziphumo ebezingalindelekanga, ukunika unyango oluchanekileyo kunye nolomntu womhlaza.
unyango Umhlaza iye yavela kakhulu, nge ukuhanjiswa kweyeza elijoliswe kumhlaza evelayo njengesicwangciso esithembisayo. Le ndlela ijolise ekuhambiseni iziyobisi ngokukhethekileyo kwiiseli zomhlaza, ukwandisa iziphumo zonyango ngelixa unciphisa umonakalo kwizicubu eziphilileyo. Ngokungafaniyo nechemotherapy eqhelekileyo, ehambisa amachiza kuwo wonke umzimba, ukuhanjiswa okujoliswe kuko kusebenzisa iindlela ezahlukeneyo ukujolisa ngqo kwiiseli zomhlaza.
Ichemotherapy yesiNtu ihlala ikhokelela kwiziphumo ebezingalindelekanga ezibalulekileyo kuba ichaphazela zombini iiseli ezinomhlaza kunye nezisempilweni. Ukuhanjiswa kweziyobisi ekujoliswe kuzo kumhlaza inikeza isisombululo ngokuhambisa iziyobisi ngokuthe ngqo kwindawo yethumba. Oku kunciphisa ubutyhefu benkqubo, kuphucula ukusebenza kwechiza, kwaye kunokunyusa umgangatho wobomi besigulana.
Kusetyenziswa izicwangciso ezininzi zokuyila ukuhanjiswa kweyeza elijoliswe kumhlaza, ngalinye lineengenelo nemida yalo.
I-Nanoparticles ngamasuntswana amancinci (1-100 nm) eyenzelwe ukuhlanganisa kunye nokuhambisa iziyobisi kwiiseli zomhlaza. Zinokuqulunqwa ukuba zijolise kwii-receptors ezithile kwiiseli zomhlaza, ezifana ne-EGFR okanye i-HER2. I-Liposomes, i-polymeric nanoparticles, kunye ne-inorganic nanoparticles zisetyenziswa ngokuqhelekileyo. Isiphumo esiphuculweyo sokuphumelela kunye nokugcinwa (EPR) sivumela ii-nanoparticles ukuba ziqokelele ngokungaqhelekanga kwizicubu ze-tumor ngenxa ye-vasculature evuzayo.
Umzekelo: I-Doxil, i-liposomal doxorubicin, lichiza elifumaneka kwi-nanoparticle-based based drug esetyenziselwa ukunyanga umhlaza we-ovarian kunye ne-myeloma eninzi.
Ii-ADCs ziquka i-antibody ye-monoclonal edityaniswe neyeza le-cytotoxic. I-antibody ibophelela ngokukodwa kwi-antigen ekujoliswe kuyo kwiiseli zomhlaza, ezikhokelela ekufakweni ngaphakathi kwe-ADC kunye nokukhululwa kweyeza ngaphakathi kweseli.
Umzekelo: I-Adcetris (i-brentuximab vedotin) ijolise kwi-CD30, iprotheni efunyenwe kwiiseli ezithile ze-lymphoma, ihambisa i-microtubule-disrupting agent.
Ii-CPP zilandelelwano ezimfutshane ze-amino acid eziququzelela ukungena kwamachiza okanye i-nanoparticles kwiiseli. Ziyakwazi ukudityaniswa kwii-agent zonyango okanye i-nanoparticles ukunyusa ukuthathwa kweselula.
Esi sicwangciso sibandakanya i-receptors ekujoliswe kuyo echazwe ngokugqithiseleyo kwiiseli zomhlaza. I-Ligands okanye ii-antibodies ezibophelela kula ma-receptors zisetyenziselwa ukuhambisa iziyobisi okanye i-nanoparticles nge-endocytosis.
Iziko loPhando loMhlaza laseShandong Baofa lizibandakanya ngokukhutheleyo kuphando nokuphuhlisa inoveli ukuhanjiswa kweyeza elijoliswe kumhlaza iinkqubo. Uphando lwabo lujolise kwiindlela zomntu ngamnye eziqwalasela iprofayili eyodwa yofuzo kunye nemolekyuli yezigulane ezizimeleyo, ezijolise ekuphuculeni iziphumo zonyango kunye nokunciphisa iziphumo ebezingalindelekanga.
IShandong Baofa Cancer Research Institute isebenza nezibhedlele ezifana neShandong Baofa Cancer Hospital (https://baofahospital.com) ukuqhuba iimvavanyo zeklinikhi kunye nokuguqulela iziphumo zophando kwizicelo ezisebenzayo.
Ukuhanjiswa kweziyobisi ekujoliswe kuzo kumhlaza inika iingenelo ezininzi eziphambili kwichemotherapy eqhelekileyo:
Nangona isithembiso sayo, ukuhanjiswa kweyeza elijoliswe kumhlaza ijongene nemingeni emininzi:
Abaliqela ukuhanjiswa kweyeza elijoliswe kumhlaza Iinkqubo okwangoku zivunyiwe ukuba zisetyenziswe ekliniki:
| Igama leziyobisi | Ekujoliswe kuko | Uhlobo lomhlaza | Indlela yokuhanjiswa |
|---|---|---|---|
| Doxil (liposomal doxorubicin) | Ujoliso olungenakwenziwa ngesiphumo se-EPR | Umhlaza we-Ovarian, i-myeloma emininzi | Iiposomes |
| Adcetris (brentuximab vedotin) | CD30 | I-Hodgkin lymphoma, i-Anaplastic enkulu ye-cell lymphoma | Antibody-drug conjugate (ADC) |
| Kadcyla (trastuzumab emtansine) | HER2 | HER2-positive umhlaza webele | Antibody-drug conjugate (ADC) |
Intsimi ye ukuhanjiswa kweyeza elijoliswe kumhlaza ikhula ngokukhawuleza. Uphando lwexesha elizayo luya kugxila koku:
Ukuhanjiswa kweziyobisi ekujoliswe kuzo kumhlaza unesithembiso esikhulu sokuphucula unyango lomhlaza kunye neziphumo zesigulana. Njengoko uphando luqhubeka, sinokulindela ukubona okusebenzayo ngakumbi kunye nokwenzelwa umntu ukuhanjiswa kweyeza elijoliswe kumhlaza amaqhinga avelayo, ekugqibeleni akhokelela kukhathalelo olungcono lomhlaza.